ANVS
vs
S&P 500
ANVS
S&P 500
Over the past 12 months, ANVS has underperformed S&P 500, delivering a return of -18% compared to the S&P 500's +14% growth.
Stocks Performance
ANVS vs S&P 500
Performance Gap
ANVS vs S&P 500
Performance By Year
ANVS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Annovis Bio Inc
Glance View
Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania and currently employs 3 full-time employees. The company went IPO on 2020-01-29. The firm is engaged in developing treatments for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease in Down syndrome (AD-DS). The firm's lead compound, ANVS401, is an orally administered drug being developed for chronic indications such as AD, PD and AD-DS. The firm's ANVS405 compound is being developed for acute indications, focused on protecting the brain after Traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as ANVS401, but it is given intravenously in cases of acute head and brain trauma. The firm is also developing its compound, ANVS301 to increase cognitive capability in later stages of AD and dementia.